Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Cerus Corporation

Market Cap 513M 442M 407M 382M 717M 48.48B 724M 4.81B 1.88B 23.74B 1.92B 1.88B 82.15B P/E Ratio 2026 *
-76.8x
P/E Ratio 2027 * -769x
Enterprise Value 513M 442M 407M 382M 717M 48.48B 724M 4.81B 1.88B 23.74B 1.92B 1.88B 82.15B EV / Sales 2026 *
2.15x
EV / Sales 2027 * 1.97x
Free-Float
96.59%
Yield 2026 *
-
Yield 2027 * -
1 day-0.59%
1 week-2.12%
Current month-16.28%
1 month+8.76%
3 months+41.39%
6 months+26.62%
Current year+23.54%
1 week 2.46
Extreme 2.46
2.73
1 month 2.34
Extreme 2.34
3.13
Current year 1.62
Extreme 1.62
3.15
1 year 1.15
Extreme 1.15
3.15
3 years 1.12
Extreme 1.12
3.15
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 59 21/04/2011
Chief Tech/Sci/R&D Officer 82 01/07/2015
Director of Finance/CFO 54 04/05/2009
Director TitleAgeSince
Chairman 59 20/06/2025
Director/Board Member 72 24/03/2014
Director/Board Member 66 09/10/2018
Date Insider Type Main position Quantity % Market Cap.
06-09Sell

Director

-20,454 0.0102%
06-02Free

Director

60,000 0.0299%
06-02Free

Director

60,000 0.0299%
Change 5-day change 1-year change 3-year change Capi.($)
-0.59%-2.12%+80.50%-4.68% 513M
-1.24%+2.42%-18.11%+4.46% 120B
-0.18%-0.70%+4.48%-9.59% 12.9B
+1.93%+5.71%+28.75%+91.04% 7.44B
-0.70%-5.33%-47.25%-70.68% 4.2B
+0.78%+4.91%+12.86%+34.26% 2.55B
-0.61%+9.37%-16.28%-15.40% 1.8B
-1.86%-7.48%+3.12%-12.69% 1.66B
-0.91%-11.60%+150.66%+119.28% 1.37B
Average -0.34%+0.64%+22.08%+15.11% 16.9B
Weighted average by Cap. -0.89%+1.78%-12.08%+6.51%

Financials

2026 *2027 *
Net sales 238M 205M 189M 177M 333M 22.5B 336M 2.23B 872M 11.02B 894M 875M 38.13B 260M 224M 206M 193M 363M 24.56B 367M 2.44B 952M 12.03B 975M 954M 41.61B
Net income -6.24M -5.38M -4.95M -4.64M -8.72M -590M -8.81M -58.49M -22.85M -289M -23.41M -22.91M -999M -479K -413K -380K -357K -670K -45.3M -677K -4.49M -1.76M -22.18M -1.8M -1.76M -76.76M
Net Debt - -
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
16/06/26 2.540 $ -0.78% 1,067,890
12/06/26 2.560 $ -1.16% 2,235,661
11/06/26 2.590 $ +1.17% 3,859,805
10/06/26 2.560 $ -0.78% 1,840,934
09/06/26 2.580 $ -0.77% 2,240,904
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.560USD
Average target price
4.667USD
Spread / Average Target
+82.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!